Product Description
Mechanisms of Action: HCV-NS5A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis A|Hepatitis C, Chronic
Phase 1: Hepatitis C, Chronic|Hepatitis C
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01919125 |
MK-1894-008 | P1 |
Completed |
Hepatitis C, Chronic |
2014-02-01 |
2022-05-04 |
Primary Endpoints |
|
NCT01907724 |
MK-1894-007 | P1 |
Completed |
Hepatitis C, Chronic |
2013-08-01 |
2022-05-04 |
Primary Endpoints |
|
NCT01813513 |
MK-1894-004 | P1 |
Completed |
Hepatitis C, Chronic |
2013-07-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT01813552 |
MK-1894-006 | P1 |
Completed |
Hepatitis C, Chronic |
2013-03-01 |
2022-05-04 |
Primary Endpoints |
|
NCT01335607 |
MK-2355-006 | P1 |
Completed |
Hepatitis C |
2011-05-01 |
2022-05-04 |
||
NCT01852604 |
MK-1894-005 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2015-04-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT01508156 |
MK-1894-001 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2012-07-01 |
2022-05-04 |
Recent News Events
Date |
Type |
Title |
|---|